The COVID-19 pandemic: is our medicine still evidence-based?

Area of Science:

• Infectious Diseases
• Clinical Pharmacology
• Evidence-Based Medicine

Background:

• The efficacy of antiviral therapies for COVID-19 has not yet been established through randomized controlled trials.
• Physicians are currently prescribing various antiviral drugs for COVID-19 patients, often without definitive evidence of benefit.
• This practice deviates from the principles of evidence-based medicine, highlighting a gap in clinical knowledge.

Purpose of the Study:

• To emphasize the critical need for evidence-based knowledge regarding COVID-19 treatment.
• To advocate for research that informs routine care practices for ameliorating patient symptoms.
• To guide effective strategies for combating the pathology of COVID-19.

Main Methods:

• This study is a critical review of the current treatment landscape for COVID-19.
• It highlights the absence of high-level evidence from randomized controlled trials.
• It calls for future research to establish evidence-based guidelines.

Main Results:

• There is a lack of definitive scientific evidence from randomized controlled trials supporting the efficacy of antiviral therapies for COVID-19.
• Current clinical practice involves widespread prescription of antiviral medications without robust empirical support.
• A significant gap exists between clinical practice and evidence-based medicine in COVID-19 management.

Conclusions:

• Urgent need for rigorous, evidence-based research to validate or refute the efficacy of antiviral treatments for COVID-19.
• Development of evidence-based guidelines is essential for optimizing routine care and improving patient outcomes.
• Future research should focus on identifying effective interventions to alleviate symptoms and combat COVID-19 pathology.